论文部分内容阅读
结核菌依靠它的生物适应机制,对现有常用抗结核药物易产生耐药性。有关这方面的报导很多。作者最近曾报告在219例复治病例中,继发耐药率高达92％(203例)。临床上为了控制和延缓耐药性的产生,多采用抗结核药物的联合应用。过去我们只做三种主要抗痨药物(异菸肼H、链霉素S、对氨柳酸钠P)的单一药物的耐药性实验。近两年来,为了给临床提供科学依据,我们开展了三种主要抗结核药物的联合耐药性实验。现将106株(例)实验结果初步报告如下: 实验材料和方法培养基:采用小川培养基。药物浓度:含药浓度,见表一。
Mycobacterium rely on its biological adaptation mechanism, the existing commonly used anti-TB drugs prone to drug resistance. There is a lot of coverage in this area. The authors recently reported that in 219 cases of retreatment, the rate of secondary resistance was as high as 92% (203 cases). Clinically in order to control and delay the emergence of drug resistance, and more use of anti-TB drugs in combination. In the past we used to do only one of three major anti-tuberculosis drugs (isoniazid H, streptomycin S, vs. sodium P). In the past two years, in order to provide a scientific basis for clinical trials, we conducted joint drug resistance trials of three major anti-TB drugs. Now 106 (example) preliminary report of the experimental results are as follows: Experimental Materials and Methods Medium: using Ogawa medium. Drug concentration: drug concentration, see Table 1.